Biomea Fusion's Icovamenib Data Selected for 3 ADA Late-Breaking Posters
Biomea Fusion announced that three abstracts for its investigational oral menin inhibitor, icovamenib, have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026. The presentations will include data from both Type 1 and Type 2 diabetes studies, highlighting icovamenib's potential to improve beta cell function, support metabolic health, and improve endogenous insulin secretion. This marks a significant step in the clinical development of the Phase 2 drug.
Key Highlights
- Biomea Fusion's icovamenib data selected for three late-breaking posters at ADA 86th Scientific Sessions.
- Presentations on June 7, 2026, will cover Type 1 and Type 2 diabetes data.
- Icovamenib shows potential to improve beta cell function and metabolic health.
- COVALENT-112 study results indicate improved endogenous insulin secretion in Type 1 diabetes.
- COVALENT-111 subgroup analysis shows glycemic improvements in T2D on GLP-1 therapy.
- Icovamenib is an investigational oral menin inhibitor in Phase 2 clinical development.
Price Impact
More from BMEA
Biomea Fusion Q2 Net Loss Narrows to $8.3M; Going Concern Doubt Raised
Biomea Fusion Reports Q2 Net Loss $8.3M; Advances Diabetes & Obesity Trials
Biomea Fusion Icovamenib Data Shows T1D/T2D Benefits, Metabolic Health